Mineralys Therapeutics Q3 net loss rises to $57.3 million from $36.9 million a year earlier
Mineralys Therapeutics reported a third-quarter 2026 net loss of $57.3 million, up from $36.9 million a year earlier, as general and administrative expenses rose to $37.4 million to prepare for commercial launch of lorundrostat. The company said its FDA review of lorundrostat has a PDUFA target date of December 22, 2026, and that its cash should fund operations into 2028. A director, Derek DiRocco, also plans to resign from the board effective December 31, 2026.
Key points
- Net loss was $57.3 million, or $0.64 per share, versus $36.9 million, or $0.52 per share, a year earlier.
- General and administrative expenses were $37.4 million, up from $9.7 million, driven by $15.4 million in higher professional fees and $11.4 million in higher personnel costs.
- Cash, cash equivalents and investments were $624.7 million at September 30, 2026, versus $656.6 million at December 31, 2025.
- Director Derek DiRocco will resign from the board effective December 31, 2026, and said the decision was not due to any disagreement with the company.
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.